A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions

Healthy

Interventions

DRUG

JNJ-54175446

JNJ-54175446 up to 600 mg suspension for oral dose administration.

DRUG

18F-JNJ-64413739

18F-JNJ-64413739 fluid for injection administered intravenously.

Trial Locations (1)

UZ Leuven, Leuven